ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data

ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data

Source: 
Fierce Biotech
snippet: 

AstraZeneca, home of cancer blockbusters like Tagrisso and Daiichi Sankyo-partnered Enhertu, wants to elevate its cancer pipeline and is sharing a peek at data from three bispecific antibody candidates at this year's European Society for Medical Oncology (ESMO) Congress.